Cost-effectiveness analysis of an orphan drug tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing.

导出 LinkOut

翻译打印收藏纠错

作者： Shaohong,Luo ^[1] ; Chen,Xie ^[2] ; Ningning,Lin ^[1] ; Dong,Lin ^[2] ; Dian,Gu ^[1] ; Shen,Lin ^[2] ; Xiaoting,Huang ^[1] ; Xiongwei,Xu ^[2] ; Xiuhua,Weng ^[3]

作者单位： Department of Pharmacy, the First Affiliated Hospital of Fujian Medical University. ^[1] Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital of Fujian Medical University, Fuzhou, China. ^[2] Institute for Health & Aging, University of California, San Francisco, California, USA. ^[3]

主题词人类(Humans);黑色素瘤(Melanoma);孤儿药生产(Orphan Drug Production);费用效益分析(Cost-Benefit Analysis);皮肤肿瘤(Skin Neoplasms)

DOI 10.1097/CMR.0000000000000919

PMID 37650713

发布时间 2023-10-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交